标题
mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
作者
关键词
Docetaxel, Androgen Receptor, Gefitinib, Everolimus, mTOR Inhibitor
出版物
Targeted Oncology
Volume 12, Issue 1, Pages 47-59
出版商
Springer Nature
发表日期
2016-08-09
DOI
10.1007/s11523-016-0453-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review
- (2016) Archana Anantharaman et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Targeting molecular resistance in castration-resistant prostate cancer
- (2015) Thenappan Chandrasekar et al. BMC Medicine
- Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications
- (2015) Dana E. Rathkopf et al. CANCER
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
- (2015) Kevin D. Courtney et al. Clinical Genitourinary Cancer
- Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance
- (2015) Lei Chang et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Persistent androgen receptor addiction in castration-resistant prostate cancer
- (2015) Michael T. Schweizer et al. Journal of Hematology & Oncology
- Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer
- (2015) U. Emmenegger et al. ONCOLOGIST
- Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis
- (2015) A D Raval et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
- (2015) Ulka Vaishampayan et al. UROLOGY
- Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer
- (2015) Wenqing Qi et al. Oncotarget
- PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
- (2014) AndrewC Hsieh et al. ASIAN JOURNAL OF ANDROLOGY
- Metformin Activates AMP-activated Protein Kinase by Promoting Formation of the αβγ Heterotrimeric Complex
- (2014) Shumei Meng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Crosstalking between Androgen and PI3K/AKT Signaling Pathways in Prostate Cancer Cells
- (2014) Suk Hyung Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Should we give metformin to all men with CRPC?
- (2014) Melanie Clyne Nature Reviews Urology
- Preserving Flow in Liver Transplant Recipients: mTOR Inhibitors Everolimus and Sirolimus Are Not Peas From a Pod
- (2013) M. Bhat et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells
- (2013) Paolo Fagone et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
- (2013) K Kruczek et al. BRITISH JOURNAL OF CANCER
- Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)
- (2013) Hielke J. Meulenbeld et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
- (2013) Andrew J. Armstrong et al. Clinical Genitourinary Cancer
- Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
- (2013) Rhonda L Bitting et al. ENDOCRINE-RELATED CANCER
- Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
- (2013) Arnoud J. Templeton et al. EUROPEAN UROLOGY
- Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts
- (2013) Alexandre Ingels et al. INTERNATIONAL JOURNAL OF CANCER
- Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer ProgressionIn Vivo
- (2013) Christian Thomas et al. MOLECULAR CANCER THERAPEUTICS
- Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
- (2012) Mari Nakabayashi et al. BJU INTERNATIONAL
- Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer
- (2012) Robert J. Amato et al. Clinical Genitourinary Cancer
- Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality
- (2012) Daniel E. Spratt et al. EUROPEAN UROLOGY
- Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
- (2012) Sheng Tai et al. MOLECULAR CANCER THERAPEUTICS
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
- (2011) Emmanuel S. Antonarakis et al. BJU INTERNATIONAL
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
- (2011) Aung Naing et al. CLINICAL CANCER RESEARCH
- End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice
- (2011) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment
- (2011) R. Aggarwal et al. ONCOLOGIST
- Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment
- (2010) Carlos García-Echeverría BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine
- (2010) Antonella Perotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibitors of mTOR
- (2010) H.-J. Klumpen et al. ONCOLOGIST
- Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
- (2009) Gerhardt Attard et al. CANCER CELL
- Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis
- (2009) C. Nardella et al. Science Signaling
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer
- (2008) Robert J. Amato et al. Clinical Genitourinary Cancer
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started